Role of tumor necrosis factor-alpha in the pathogenesis of a trial fibrillation

Chinese Medical Journal

Volumn 124, Issue 13, 2011, Pages 1976-1982

  Deng, Hai ^a   Xue, Yu Mei ^a   Zhan, Xian Zhang ^a   Liao, Hong Tao ^a   Guo, Hui Ming ^a   Wu, Shu Lin ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Atrial fibrillation; Left atrial diameter; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT ATRIUM; HEART SIZE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATIC HEART DISEASE; SINUS RHYTHM; WESTERN BLOTTING;

AGED; ATRIAL FIBRILLATION; BLOTTING, WESTERN; FEMALE; HEART ATRIA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960065069     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.13.010     Document Type: Article

References (33)

1. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-149.
2. Frustaci A, Caldarulo M, Buffon A, Bellocci F, Fennici R, Melina D. Cardiac biopsy in patients with ''primary'' atrial fibrillation. Histologic evidence of occult myocardial diseases. Chest 1991; 100: 303-306.
3. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for a trial fibrillation. Circulation 2003; 108: 3006-3010.
4. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with a trial fibrillation. Int J Cardiol 2005; 98: 73-77.
5. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent a trial fibrillation. Eur Heart J 2004; 25: 1100-1107.
6. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91: 1303-1305.
7. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
8. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation: Is there an association with early recurrence rates? Int J Clin Pract 2005; 59: 881-885.
9. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004; 95: 1140-1153.
10. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-444.
11. Rizos I, Rigopoulos AG, Kalogeropoulos AS, Tsiodras S, Dragomanovits S, Sakadakis EA, et al. Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. J Hum Hypertens 2010; 24: 447-457.
12. Brundel BJ, Ausma J, van Gelder IC, Van der Want JJ, van Gilst WH, Crijns HJ, et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002; 54: 380-389.
13. Buonaquro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66: 7159-7167.
14. Katayama A, Oqino T, Bandoh N, Nonaka S, Harabuchi Y. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 2937-2946.
15. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
16. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-777.
17. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008; 94: 200-204.
18. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997; 18: 111-115.
19. Ishida K, Kimura F, Imamaki M, Ishida A, Shimura H, Kohno H, et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg 2006; 29: 501-505.
20. 2+ transients. FEBS Lett 1995; 376: 24-30.
21. Wu XY, Han SP, Ren MY, Chang Y, Yu FX. The role of NF-kappaB activation in lipopolysaccharide induced keratitis in rats. Chin Med J 2005; 118: 1893-1899.
22. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappa B and increased tumor necrosis factor-alpha in atial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 23: 1-6.
23. Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J. TNF-α induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. Am J Physiol Heart Circ Physiol 2007; 293: H2726-H2737.
24. Cailleret M, Amadou A, Andrieu-Abadie N, Nawrocki A, Adamy C, Ait-Mamar B, et al. N-acetylcysteine prevents the dileteriou effect of tumor necrosis factor-αon calcium transients and contraction. Circulation 2004; 109: 406-411.
25. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56: 375-380.
26. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346-353.
27. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-767.
28. Roldan V, Marin F, Martinez JG, Garcia-Herola A, Sogorb F, Lip GY. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005; 95: 881-882.
29. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of non rheumatic atrial fibrillation: the Framingham Heart Study. Circulation 1994; 89: 724-730.
30. Parkash R, Green MS, Kerr CR, Connolly SJ, Klein GJ, Sheldon R, et al. The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J 2004; 148: 649-654.
31. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial size:physiologic determinants and clinical applications. J Am Coll Cardiol 2006; 47: 2357-2363.
32. Sanders P, Berenfeld O, Hocini M, Vaidyanathan R, Hsu LF, Garrigue S, et al. Spectral analysis identifies sites of high-frequecy activity maintaining atrial fibrillation in humans. Circulation 2005; 112: 789-797.
33. Swartz MF, Fink GW, Lutz CJ, Taffet SM, Berenfeld O, Vikstrom KL, et al. Left versus right atrial difference in dominant frequency, K+ channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm 2009; 6: 1415-1422.